Magnetic resonance imaging of the residual disease in the breast cancer patients treated with neoadjuvant chemotherapy

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCC-10000827

Enrollment

Unknown

Registered

2010-04-05

Start date

2010-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Total:Magnetic resonance imaging, including noncontrast scan, diffusion weighted imaging, dynamic contrast enhanced MRI, and magnetic resonance spectroscopy.

Eligibility

Sex/Gender

Female

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The locally advanced breast cancer patients treated with neoadjuvant chemotherapy; 2. The tumors showing partial response to neoadjuvant chemotherapy; 3. The patients undergoing mastectomy after neoadjuvant chemotherapy; 4. The patients agree to participate in the trials and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Tumors showing complete response, or progressive disease, or stable disease to neoadjuvant chemotherapy; 2. The patients discontinuing neoadjuvant chemotherapy; 3. Having contraindication of MRI.

Design outcomes

Secondary

Measure	Time frame
The breast MR images, before and after neoadjuvant chemotherapy, are analyzed: 1. shape, number; 2. tumor size; 3. Apparent diffusion coefficient; 4. Dynamic enhancement;	—

Primary

Measure	Time frame
The sensitivity, specificity, accuracy;	—

Countries

China

Contacts

Public ContactJun Jiang

jcbd@medmail.com.cn+86 023 68754160

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026